GLP1R-imaging in Post-RYGB Hypoglycemia

NCT05597475 · Unknown status

Last updated 2026-05-28

This clinical trial is testing a new imaging method to detect changes in the pancreas of people who experience low blood sugar after weight-loss surgery.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design open-label (no blinding) basic-science study

Participants 24 people Planned (estimated).

Who can join Ages 18+ · all sexes Healthy volunteers accepted.

Timeline Started 2016-11 · est. completion 2024-12

Where 1 site · Netherlands

What this study is testing ClinicalTrials.gov NCT05597475 ↗

Description as written by the study sponsor.

In order to evaluate the difference in beta cell mass in patients with and without hyperinsulinemic hypoglycemia after Roux en Y gastric bypass (RYGB) investigators aim to compare quantitative PET imaging of the pancreas between these patient groups. These highly relevant data will provide investigators with more information on the possible role of beta cell mass in the mechanisms of hyperinsulinemic hypoglycemia bariatric surgery.

Treatments tested

GLP-1R PET also known as Meal tolerance test, Arginine stimulation test Diagnostic test

Beta cell function (tests) and measure for beta cell mass (PET)

Main thing measured	Pancreatic uptake of 68Ga-NODAGA-exendin-4
Sponsor	Rijnstate Hospital
Conditions studied	Obesity, Hypoglycemia Post Gastric Bypass Surgery, Hyperinsulinemic Hypoglycemia
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05597475 ↗